StemCells Gains 5% on Neural Stem Cell Trial in Spinal Cord Injury

By Dr. Matthew Watson



Shares of StemCells (STEM) are up 5.85% after the company announced that it will initiate the Phase I/II clinical trial of its proprietary HuCNS-SC human neural stem cells in chronic spinal cord injury. The trial is now open for enrollment, and will accept patients with both complete and incomplete degrees of paralysis who are three to twelve months post-injury. It is being conducted in Switzerland at the Balgrist University Hospital, University of Zurich

See the rest here:
StemCells Gains 5% on Neural Stem Cell Trial in Spinal Cord Injury

Related Post


categoriaSpinal Cord Stem Cells commentoComments Off on StemCells Gains 5% on Neural Stem Cell Trial in Spinal Cord Injury | dataOctober 5th, 2011

About...

This author published 5472 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research

Copyright :: 2024